Compass Therapeutics (NASDAQ:CMPX) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Compass Therapeutics (NASDAQ:CMPX) released its earnings results on Monday. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03), FiscalAI reports.

Compass Therapeutics Price Performance

NASDAQ CMPX opened at $0.76 on Monday. The company’s 50 day simple moving average is $1.29 and its 200 day simple moving average is $3.10. Compass Therapeutics has a 12 month low of $0.67 and a 12 month high of $6.88. The company has a market capitalization of $136.65 million, a P/E ratio of -1.90 and a beta of 1.06.

Analyst Upgrades and Downgrades

CMPX has been the subject of a number of research reports. Guggenheim decreased their price target on Compass Therapeutics to $4.00 and set a “buy” rating for the company in a research note on Wednesday, September 23rd. Citizens Jmp dropped their price objective on Compass Therapeutics to $4.00 and set a “market outperform” rating on the stock in a research note on Wednesday, September 23rd. Piper Sandler upped their price objective on Compass Therapeutics from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Wall Street Zen cut Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Compass Therapeutics in a research note on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.25.

About Compass Therapeutics

Compass Therapeutics is a clinical-stage biotechnology company focused on developing antibody-based medicines for cancer. The company’s research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving immune responses in patients with cancer.

Its lead product candidate, CTX-471, is a fully human monoclonal antibody designed to activate CD137, also known as 4-1BB. CD137 is a co-stimulatory receptor found on immune cells, including T cells and natural killer cells.